跳至主要内容

FAQ – Solvent Residue Handling Manual for Active Pharmaceutical Ingredients

 The residue of solvent in APIs is one of the key issues to be mindful of during drug manufacturing. When solvent residue exists in the APIs or formulations, it may have adverse effects on the stability, purity, and efficacy of the drugs.  Overcoming the difficulties of solvent residue in APIs involves multiple aspects, such as selecting appropriate solvents, optimizing synthesis conditions, and employing effective methods for solvent removal.  At the same time, it is essential to employ scientific testing methods to monitor and ensure that solvent residues are within acceptable limits. Establishing highly sensitive and accurate analytical detection methods is indispensable to meet international standards for residual solvent detection, thus safeguarding the safety and efficacy of medication for patients.  



Medicilon Cloud Lecture invites the head of the Process Analysis Department,  Maodun Xie to share with us the challenges and solutions regarding solvent residue in APIs during preclinical operations.

Q: Benzene is used in the second to last step of the starting material. My synthesis process for the API consists of four steps. Benzene should be able to be removed in subsequent steps of the process, resulting in a low possibility of residue in the API. Does this mean further research is unnecessary?

Maodun XieWhether further research is required depends on whether the manufacturer of the raw materials you purchase has conducted relevant studies.  If the manufacturer has conducted research according to the standards for APIs, then you may not need to conduct further research.  But if the manufacturer has not conducted relevant research, then it is still necessary to study the possibility of residue.  Generally, purchased raw materials are essentially reagent-grade, and they are rarely studied for benzene residue according to API standards. Therefore, it is highly likely that research in this area will be necessary.

Q: If the process only involves 3 types of solvents, can we directly use the method of drying and weighing loss for detection?

Maodun XieWhether to use the method of drying and weighing loss for sample detection mainly depends on whether the sample is thermally stable.  If it’s a solid sample, it’s more likely to be thermally stable. In ICH-Q3C, drying and weighing loss can be used for detection, with a limit requirement of less than 0.5%.  However, it is recommended to choose the methods with stronger specificity and higher accuracy for confirmation. If the results from testing representative batches are similar to the results from drying and weighing loss, then drying and weighing loss can be used for testing in subsequent production.

Q: Can LD50 be used to calculate limits?

Maodun Xie: This is not possible. The National Medical Products Administration stated clearly in 2022 that LD50 values cannot be used in limit setting. LD50 represents the median lethal dose, indicating high toxicity and therefore cannot be used to calculate safe limits.


Analytical Testing Center

Medicilon Analytical Testing Center is located in Medicilon Nanhui Park, with a total analytical laboratory area of 2800 square meters. The established GMP system has passed NMPA on-site inspections and actively promotes CNAS certification.

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati